Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar-Apr;21(2):355-358.
doi: 10.4103/ijem.IJEM_555_16.

Levosulpiride and Serum Prolactin Levels

Mohammad Shafi Kuchay  1 , Ambrish Mithal  1
Affiliations

Levosulpiride and Serum Prolactin Levels

Mohammad Shafi Kuchay et al. Indian J Endocrinol Metab. 2017 Mar-Apr.

Abstract

Levosulpiride is the levorotatory enantiomer of sulpiride used in dyspeptic syndromes of various etiologies. The prokinetic effect of levosulpiride is mediated through the blockade of enteric inhibitory dopaminergic type 2 (D2) receptors. The antagonism of central D2 receptors leads to both therapeutic (e.g. antiemetic effect due to D2 receptor blockade in the chemoreceptor trigger zone) and adverse (including hyperprolactinemia) effects. Dopamine is the main endogenous inhibitor of prolactin synthesis and secretion in the anterior pituitary. Levosulpiride causes significant elevation of serum prolactin levels in significant number of patients. The resultant hyperprolactinemia often manifests as distressing menstrual abnormalities and galactorrhoea in females. A significant number of patients who use levosulpiride develop serum prolactin levels of > 200 ng/mL that goes against the classical textbook teaching where pituitary tumor is supposed to be the mostly likely cause. Careful drug history in patients presenting with high serum prolactin levels will be of great help in reaching the exact diagnosis and avoiding unnecessary brain imaging.

Keywords: Galactorrhoea; hyperprolactinemia; levosulpiride.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Prolactin axis
See this image and copyright information in PMC

References

    1. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: Structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523–631. - PubMed
    1. Pan JT. Neuroendocrine functions of dopamine. In: Stone TW, editor. CNS Neurotransmitters and Neuromodulators: Dopamine. Boca Raton, FL: CRC Press; 1996. pp. 213–31.
    1. Manzanares J, Wagner EJ, LaVigne SD, Lookingland KJ, Moore KE. Sexual differences in kappa opioid receptor-mediated regulation of tuberoinfundibular dopaminergic neurons. Neuroendocrinology. 1992;55:301–7. - PubMed
    1. Toney TW, Manzanares J, Moore KE, Lookingland KJ. Sexual differences in the stimulatory effects of bombesin on tuberoinfundibular dopaminergic neurons. Brain Res. 1992;598:279–85. - PubMed
    1. Moore KE, Demarest KT, Lookingland KJ. Stress, prolactin and hypothalamic dopaminergic neurons. Neuropharmacology. 1987;26:801–8. - PubMed